Hormonal
Untreated thyroid dysfunction (both hyper- and hypothyroidism) impairs metabolic control in diabetic patients, exacerbating glycemic instability and increasing the risk of microvascular complications.
If you have diabetes, your thyroid health directly impacts your blood sugar control. Untreated thyroid issues (even subclinical ones) can make your diabetes harder to manage. You should be screened for thyroid dysfunction (TSH, TPO antibodies) regularly, and if found, treating the thyroid issue is essential to achieving stable glucose levels.
An untreated thyroid dysfunction can impair the metabolic control of diabetic patients, and this association can have important repercussions on the outcome of both of these disorders.
Why this rating
Based on a comprehensive review of multiple longitudinal studies, meta-analyses, and population-based cohorts (NHANES, HUNT, Rotterdam) cited in the text.
Source
Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders
Bernadette Biondi et al. · Endocrine Reviews · 2019
DOI 10.1210/er.2018-00163
More from this paper
- Autoimmune thyroid disease (AITD) is significantly more prevalent in patients with Type 1 Diabetes (T1D) than in the general population, sharing common genetic susceptibility factors.Strong
- Subclinical hypothyroidism (SHypo) is more prevalent in patients with Type 2 Diabetes (T2D) than in the general population and is associated with an increased risk of diabetic microvascular complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →